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Abstract 
To quantify the full range of tryptophan metabolites along the kynurenine pathway, a liquid 
chromatography – tandem mass spectrometry method was developed and used to analyse 
brain extracts of rodents treated with the kynurenine-3-mono-oxygenase (KMO) inhibitor 
Ro61-8048 during pregnancy. There were significant increases in the levels of kynurenine, 
kynurenic acid, anthranilic acid and 3-hydroxy-kynurenine (3-HK) in the maternal brain after 
5h but not 24h, while the embryos exhibited high levels of kynurenine, kynurenic acid and 
anthranilic acid after 5h which were maintained at 24h post-treatment. At 24h there was also 
a strong trend to an increase in quinolinic acid levels (P = 0.055). No significant changes 
were observed in any of the other kynurenine metabolites. The results confirm the marked 
increase in the accumulation of some neuroactive kynurenines when KMO is inhibited, and 
re-emphasise the potential importance of changes in anthranilic acid. The prolonged duration 
of metabolite accumulation in the embryo brains indicates a trapping of compounds within 
the embryonic CNS independently of maternal levels. When brains were examined from 
young mice heterozygous for the meCP2 gene – a potential model for Rett syndrome - no 
differences were noted from control mice, suggesting that the proposed roles for kynurenines 
in autism spectrum disorder are not relevant to Rett syndrome, supporting its recognition as a 
distinct, independent, condition. 
 
 
Key words: kynurenine; kynurenic acid; quinolinic acid; tryptophan metabolism; Rett 
syndrome 
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1. Introduction 
   The kynurenine pathway is the major route for tryptophan metabolism, oxidising around 
95% of free tryptophan to several compounds with biological activity at glutamate receptors, 
such as quinolinic acid (Stone  and  Perkins 1981; Stone  and  Darlington 2002) and 
kynurenic acid (Perkins  and  Stone 1982). Both these compounds have important actions on 
the N-methyl-D-aspartate (NMDA) sensitive population of receptors for glutamate at which 
quinolinic acid is an agonist and kynurenic acid is an antagonist, acting at the glycine/D-
serine site of NMDA receptors (Birch et al.,1988). 
   Concentrations of kynurenate are altered in the brains of patients with disorders such as 
schizophrenia (Nilsson et al., 2005; Schwarcz et al., 2001; see Stone  and  Darlington 2013) 
and there is strong evidence for a role also in Huntington’s disease (Forrest et al., 2010; 
Schwarcz et al., 2009). Both of these disorders involve abnormalities in brain development or 
maturation and NMDA receptors are intimately involved in the early formation of the 
embryonic brain (Iwasato et al., 2000; Ramoa et al., 2001), where they influence progenitor 
migration, axon guidance, contact formation, dendritic and spine formation (Alvarez et al., 
2007; Colonnese et al., 2005; Rajan  and  Cline 1998; Ultanir et al., 2007). Increasing the 
endogenous concentration of kynurenic acid in the CNS would, therefore, be predicted to 
modify brain development.  
   Attempts to clarify the mechanisms by which the kynurenine pathway influences these 
aspects of brain function have involved inducing changes in the brain concentrations of 
kynurenines by the administration of kynurenine (Chess et al., 2007; Pocivavsek et al., 2012), 
pharmacological inhibition of the key kynurenine metabolic enzyme kynurenine-3-mono-
oxygenase (KMO) (Forrest et al., 2013a,b; Khalil et al., 2014) or deletion of the gene for this 
enzyme in mice (Giorgini et al., 2013). Inhibition or deletion of KMO blocks the oxidation of 
kynurenine to 3-hydroxy-kynurenine, providing a higher concentration of kynurenine as a 
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substrate for kynurenine aminotransferase, which metabolises it to kynurenic acid. These 
procedures have demonstrated that during early brain formation, in utero, an inhibitor of 
KMO produces changes in the morphological, biochemical and electrophysiological 
development of the brains of the offspring (Forrest et al., 2013a,b; Khalil et al., 2014, Pisar et 
al., 2014), indicating that activity along the kynurenine pathway is actively involved in early 
brain formation and its subsequent maturation. 
     As part of these latter studies, tissue samples were analysed by HPLC to determine the 
levels of tryptophan and its major metabolites in the embryonic and maternal brain 5h and 
24h after the administration of the KMO inhibitor Ro61-8048 (Forrest et al. 2013a). 
However, samples of brain were also retained from the animals used in those studies with the 
aim of developing a highly sensitive mass spectrometry assay with which to examine changes 
simultaneously in the levels of all of the major kynurenine metabolites. This report presents 
the new data on brain levels of tryptophan, kynurenine, kynurenic acid, quinolinic acid, 
anthranilic acid, xanthurenic acid and 3-hydroxykynurenine, which support and extend our 
earlier observations. The question being addressed in the first part of the study is how KMO 
inhibition during gestation affects kynurenine metabolism in the maternal and embryonic 
brain and whether changes in the embryo could underlie the emergence of behavioural 
disorders postnatally. 
   In addition we have applied the new analysis system to examine kynurenine metabolites in 
the brains of female mice heterozygous for the X-linked Mecp2 gene. Deletion of this gene 
has been considered to represent an accurate genetic model of Rett syndrome, a 
neurodevelopmental disorder affecting females and characterised by motor, cognitive and 
autonomic impairment as well as autistic features during a childhood regression phase (Chen 
et al., 2001; Guy et al., 2001). Riederer et al. (1986) reported increased levels of kynurenine 
in post-mortem brain tissue of patients suffering from Rett syndrome but, to our knowledge, 
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no measurements have been made of the full complement of tryptophan metabolites in an 
animal model of the disorder.  The question being addressed here is whether any changes in 
kynurenine metabolism can be identified in a mouse model of Rett syndrome. 
 
 
2. Materials and Methods 
     The use of animals has been described in the original studies from which the present brain 
samples were taken (Forrest et al., 2013a,b; 2015). The work was carried out according to the 
regulations of the Animals (Scientific Procedures) act 1986 of the UK, administered and 
monitored by the Home Office. Briefly, pregnant female Wistar rats were housed alone with 
free access to food and water. Kynurenine oxidation to 3-hydroxy-kynurenine (3-HK) was 
blocked by 3,4-dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl]benzenesulphonamide (Ro61-
8048) (Rover et al., 1997) which inhibits kynurenine-3-mono-oxygenase (KMO) and shifts 
the catabolism of kynurenine away from 3-HK and towards the NMDA receptor antagonist, 
kynurenic acid (Cozzi et al., 1999; Clark et al., 2005; Forrest et al., 2013a,b). A dose of 
100mg/kg (i.p.) was identified as one suitable for repeated administration to rodents (Clark et 
al., 2005; Rodgers et al., 2009) and this was injected to the pregnant rats on days E14, E16 
and E 18 of pregnancy. Control animals were injected with the saline vehicle. Two time 
points were selected for analysis of the brains, 5h and 24h after the final administration of 
Ro61-8048, at which times the animals were killed by an overdose of anaesthetic (25% w/v 
urethane in water, 2.5g/kg i.p.) followed by cervical dislocation.  
     Female Mecp2+/- mice and the wild type litternate controls were used. The Mecp2tm1.1Bird 
mice  were originally provided as a kind gift from Professor Adrian Bird (University of 
Edinburgh) and maintained on a C57BL/6 background. Animals were maintained on 12-hour 
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light/dark cycles with free access to normal mouse food. Mice were genotyped as described 
previously (Guy et al., 2001). 
 
2.1 Brain sample extraction: 
     Samples were kept on ice throughout the extraction procedure. Mouse brains were 
prepared by homogenising in 5 vols (wt/vol) of HPLC grade methanol. Samples were 
homogenised for 30 sec using a polytron (Fisher Scientific, Loughborough, UK) then 
centrifuged at 10,000 g for 10 min at 4oC. The supernatants were collected and filtered in 
MicroSpin PVDF centrifuge tubes (Alltech, Carnforth, Lancashire, UK) using centrifugation 
at 10,000 g for 5 min at 4°C. The filtrates were stored at -80oC until mass spectrometric 
analysis.  
 
2.2 Brain sample preparation: 
      For the measurement of tryptophan and kynurenine, 10µl of blank (deionised water), 
aqueous standards, and filtered brain extracts were mixed with 150µl of stable isotope mix in 
methanol (5µl 10mM 2H5-tryptophan and  5µl 0.64mM 2H6-kynurenine sulphate in 20ml 
methanol), vortex mixed and centrifuged for 5 min at 21,000g.  
     For the measurement of kynurenic acid, anthranilic acid, 3-hydroxykynurenine, 3-
hydroxyanthranilic acid, xanthurenic acid, quinolinic acid, and picolinic acid, 150µl of blank 
(deionised water), aqueous standards, and filtered brain extracts were mixed with 15µl of the 
stable isotope mix in methanol (1:1:1, 2µM 2H5-kynurenic acid, 5µM 13C3,15N-quinolinic 
acid, 40µM 2H3-picolinic acid), vortex mixed and centrifuged for 5 min at 21,000g. 
Supernatants were transferred to a 96-deep well polypropylene plate, sealing mat applied, and 
the plate placed in the autosampler cooled to 7.5oC, awaiting injection.  
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2.3  Kynurenine metabolite analysis 
     Several groups have established the value of analytical systems based on mass 
spectrometry for components of the kynurenine pathway which represents the main route for 
the oxidation of tryptophan (Marcos et al. 2016; Galba et al. 2016; Orsatti et al. 2015; 
Schwieler et al. 2015; Savitz et al. 2015; Zhang et al. 2015; Meinitzer et al. 2014; Lesniak et 
al. 2013; Zheng et al. 2012; Moeller et al. 2012; Wilson et al. 2012; Notarangelo et al. 2012; 
Owe-Young et al. 2008; Amirkhani et al. 2002; Boni et al. 1994; Smythe et al. 2002; Kita et 
al. 2002; Saito et al. 1993). These systems have been applied to the measurement of 
individual kynurenines in blood, plasma or cerebrospinal fluid as well as components of the 
kynurenine pathway within brain tissue.  In the present work, tryptophan, kynurenine, and 
kynurenine metabolites were measured by liquid chromatography-tandem mass spectrometry 
using a CTC PAL HTS-XT, Agilent 1260 Infinity liquid chromatograph, and AB SCIEX 
6500 QTRAP mass spectrometer (AB Sciex UK Ltd, Warrington, UK). All results were 
calculated in Analyst 1.6. 
     Analytical chemicals and reagents: Tryptophan, kynurenine, kynurenic acid, anthranilic 
acid, 3-hydroxykynurenine, 3-hydroxyanthranilic acid, xanthurenic acid, picolinic acid and 
quinolinic acid were obtained from Sigma Aldrich, Poole, Dorset UK. The stable isotope 
labelled internal standards were: 2H5-tryptophan (QMx Laboratories, Thaxted, UK), 2H6-
kynurenine sulphate and 2H5-kynurenic acid (CK isotopes, Ibstock, UK), and 2H3-picolinic 
acid and 13C3,15N-quinolinic acid (LGC standards, Teddington, UK). Acetonitrile and 
methanol were obtained from Rathburn Chemicals Ltd., Walkerburn, UK and Fisher 
Scientific UK Ltd, Loughborough, UK, respectively.  
     
2.3.1  Analyte tuning and MRM optimisation: 
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     Standards of each analyte were used to automatically tune in multiple reaction monitoring 
(MRM) mode. Transition optimisations were performed manually.  Xanthurenic acid was 
significantly more sensitive in negative ion mode but, with the chromatographic conditions 
used, there was massive matrix ion suppression. Consequently, xanthurenic acid was 
measured in positive ion mode. 
 
2.3.2  Liquid chromatography-tandem mass spectrometry:  
     Analyte retention times on Chirobiotic-T columns tend to be matrix dependent, hence the 
critical requirement for the appropriate stable isotope internal standards. Consequently, where 
stable isotopes were unavailable, two separate transitions, where possible, were used to 
calculate and then confirm the result. 
 
2.3.3  Positive ion MRM mode acquisitions: 
    Isocratic chromatography of tryptophan and kynurenine (5µl injection volume; data 
acquisition time 6 min), and kynurenic acid, anthranilic acid, 3-hydroxykynurenine, 3-
hydroxyanthranilic acid, and xanthurenic acid (10µl injection volume; data acquisition time 7 
min) was performed on a 5µm ASTEC Chirobiotic –T, 10cm*2.1mm i.d. column and guard 
column, using 1:1 acetonitrile/water with 0.025% formic acid at a flow rate of 200µl/min. 
MSMS parameters: Curtain Gas: 40, CAD Gas: medium, Ion Source voltage: 5250V, Gas 
temperature: 400oC, Gas 1: 25, Gas 2: 25. 
 
2.3.4  Negative ion MRM mode acquisitions: 
     Isocratic chromatography of quinolinic acid and picolinic acid (10µl injection volume; 
data acquisition time 4 min) was performed on a 5µm ASTEC Chirobiotic –T, 10cm*2.1mm 
i.d. column and guard column, using 62.5% water/acetonitrile at a flow rate of 225µl/min. 
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MSMS parameters: Curtain Gas: 45, CAD Gas: medium, Ion Source voltage: -4500V, Gas 
temperature: 400oC, Gas 1: 30, Gas 2: 30 (see Table 1). 
 
2.4.  Data analysis and statistics 
     All data are expressed as the mean ± 1 S.E.M with n values cited in the text of Figure 
legends. Statistical comparisons were performed using two-tailed t tests between two sets of 
data or ANOVA followed by Dunnet’s test for comparing datasets to a single control set, or 
the Bonferroni test using selected datasets when multiple comparisons were required. A 
probability value of P ≤ 0.05 was used as the criterion for statistical significance.  
 
2.5  Sources of compounds 
     Sources of the compounds used for analysis are listed above in section 2.3. The KMO 
inhibitor  Ro61-8048 was partly obtained as a gift from Dr. S. Roever, F. Hoffmann-La 
Roche Ltd., Basel, Switzerland, and partly purchased from Tocris chemicals (Bristol, UK). 
 
3. Results 
3.1  Ro61-8048 treatment 
     In the adult pregnant female, the administration of Ro61-8048 produced substantial and 
highly significant increases in the concentrations of the main kynurenine metabolites of 
tryptophan in the rat brain. Tryptophan itself showed no change after 5h or 24h, whereas 
kynurenine, 3-HK and kynurenic acid showed substantially increased levels after 5h (Fig. 1). 
However, by 24h following Ro61-8048 there were no significant differences between the 
control and treated animals (Fig. 2). There was also a significant rise in the concentration of 
anthranilic acid after 5h which was no longer significant after 24h partly due to a high 
variance (Fig 2).  There was a strong trend for xanthurenic acid to be decreased by 
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approximately 50% after 24h but this was not significant (Fig. 2). Quinolinic acid levels did 
not change at either time point.  
   In the embryos, there were also highly significant increases in the concentrations of 
kynurenine, kynurenic acid and anthranilic acid at 5h (Fig. 3), but these remained high, with 
little diminution at 24h from the earlier levels (Fig. 4) in contrast to the adult data. There 
were no changes in the concentrations of 3-HK, xanthurenic acid or quinolinic acid at either 
time point. 
    The controls levels of kynurenine and kynurenic acid at 24h are comparable in the adults 
(Fig. 2) and embryos (Fig. 4). The increased levels produced by Ro61-8048, however, remain 
around 10 times the control levels in the embryos (Fig. 4) whereas levels have returned to 
approximately normal in the adults (Fig. 2).  There is a tendency for  the levels of kynurenine 
and kynurenic acid to be lower in the adults at 5h (Fig. 1) than at 24h (Fig. 2). Since all the 
animals in this study were in the late stages of gestation, the difference may be related to the 
trauma of handling and injection, procedures which could have transiently depressed 
tryptophan metabolism for up to 5h, returning towards normal by 24h. 
     Concentrations of anthranilic acid were similar in the adult and embryo brains (around 50 
pmols/g. wet weight), but 3-HK levels were significantly higher in the embryos at 5h (66.8 ± 
12.6 pmols/g wet weight) and 24h (65.68 ± 4.1 pmols/g wet weight) than  in the maternal 
brains (18.65 ± 2.51, P = 0.02 and 30.35 ± 4.9 pmols/g wet weight, P = 0.005 respectively).  
      Interestingly, given the lack of effect of Ro61-8048 on overall levels of quinolinic acid, 
the concentration of this compound is around 6 times higher in embryo brains (Figs, 3, 4) 
compared with maternal brain (Figs. 1, 2). 
 
3.2  Mecp2+/-  mice 
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   In the brain samples from female mice (3-6 weeks old) mosaic for MeCP2 expression 
(lacking functional MeCP2 in ~50% of brain cells as occurs in patients with Rett syndrome) , 
no differences were detected in any of the metabolites examined including tryptophan, 
kynurenine, kynurenic acid, xanthurenic acid and quinolinic acid, all of which were 
completely unchanged compared with wild-type littermate control animals (Fig. 5). There 
was a tendency for anthranilate levels to be reduced in the mutants, but this did not achieve 
significance.  
 
Comparison of mouse and rat data 
   Although few direct comparisons have been made of all the brain tryptophan metabolite 
levels in rat and mouse brains, it was interesting to note that the basal levels of tryptophan 
(~35 nmols/g.wet wt), kynurenine (~0.4 nmols/g.wet wt), xanthurenic acid (~12 pmols/g.wet 
wt), anthranilic acid (~40 pmols/g.wet wt) and quinolinic acid (~120 pmols/g.wet wt), were 
comparable in the mice and the untreated adult female rat controls described above. These 
values are also comparable with the baseline levels reported in previous studies (Tenorio-
Lopez et al. 2007). The levels of kynurenic acid in mice, however, were only around 12% of 
those seen in rats (~3 and ~25 pmols/g.wet wt respectively) whereas the 3-HK levels were 
approximately 4-fold higher in the mice (~80 pmols/g.wet wt) compared with the rat brains 
(~20 pmols/g.wet wt). Compared with the embryonic rat brain, concentrations of tryptophan, 
kynurenine, kynurenic acid and quinolinic acid in the mouse brains were significantly lower, 
with kynurenic acid and quinolinic acid being of the order of 10-fold less in the mice. 
   Giorgini et al. (2013) employed the same background mouse strain (C57BL/6J) for the 
original conditional knockouts of KMO as were used for the meCP2 knockout animals, 
although the KMO(-/-) animals were then back-crossed into an FVBN background. 
Nevertheless it was reassuring to note that the levels of tryptophan (~30 nmols/g.wet wt), 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
12 
 
kynurenic acid (~2.5 pmols/g.wet wt) and quinolinic acid (~100 pmols/g.wet wt) were similar 
in the normal wild type animals in the two studies. However, kynurenine levels were around 
10-fold less in the present study and anthranilic acid levels were 10-fold higher.  
 
 
4. Discussion 
   The importance of understanding the manner in which kynurenic acid and quinolinic acid 
production are regulated lies in the recognition that their modulation of NMDA receptor 
function may be relevant to several CNS disorders. These include Huntington's disease 
(Forrest et al., 2010; Schwarcz et al., 2009) schizophrenia (Schwarcz et al., 2001; Nilsson et 
al., 2005; see Stone and Darlington 2013) as well as ASD.  Strong arguments have been 
advanced that these latter two conditions may be related to environmental influences on the 
early development of the brain in utero (Casanova 2007). Given the actions of quinolinic acid 
as an NMDA receptor agonist and kynurenic acid as an antagonist, and that their 
concentrations are altered by infection (via interferon induction of cellular indoleamine-2,3-
dioxygenase, IDO) and stress (via the corticosteroid induction of hepatic tryptophan-2,3-
dioxygenase, TDO), it is reasonable to consider the possibility that changes in kynurenine 
metabolism could be involved.  
   The present results are broadly in agreement with data obtained using HPLC for kynurenine 
and kynurenic acid concentrations following KMO inhibition (Forrest et al., 2013a), which 
revealed large changes obtained 5h after Ro61-8048 but which were restored to control levels 
after 24h in the adult maternal brain while remaining elevated in the embryos. Increased 
synthesis of kynurenic acid has also been observed after Ro61-8048 treatment of mice in a 
study of the effects of cerebral malaria (Clark et al., 2005). In that study, kynurenate 
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concentrations in the brain were increased up to 100-fold, while there was little change in the 
concentrations of quinolinic acid, again supporting the profile of metabolism obtained here. 
    The ability of tryptophan metabolism to change to this extent in the formation of 
kynurenine and kynurenic acid without any significant alteration in quinolinic acid synthesis 
remains unexplained. It has been proposed that the conversion of anthranilic acid to 
quinolinic acid could account for the observation, assuming that the quinolinate synthase 
activity necessary (Baran and Schwarcz, 1990) is regulated quite precisely in order to 
compensate for the loss of quinolinic acid normally generated from kynurenine via 3-HK. 
However, in the present analysis, concentrations of 3-HK were themselves elevated after 5h 
in the adult brain, in parallel with the change in anthranilate levels, while quinolinic acid 
concentrations remained normal. Although it has not been demonstrated experimentally, it 
may be that there is a degree of inter-conversion between anthranilate and 3-HK which 
together are responsible for maintaining quinolinic acid synthesis in order to protect the 
generation of nicotinamide and nicotinamide adenine dinucleotide (NAD). It is unfortunate 
that the present analysis was unable to quantify the levels of 3-hydroxy-anthranilic acid, 
which is known to change in the opposite direction to anthranilate in some conditions, such as 
the presence of inflammation (Darlington et al., 2010). 
   It remains unclear whether Ro61-8048 is acting directly on this embryonic pathway. The 
blood-brain barrier is not fully functional until after birth, so that Ro61-8048 is likely to 
penetrate the embryonic brain far more readily than the maternal brain, resulting in the 
changes described here. However, the actual site of enzyme inhibition should not affect the 
overall results. Whether inhibition occurs within the embryo brain, within the maternal 
circulation or within the maternal brain, the consequence of enzyme inhibition should be, 
primarily, to increase the tissue levels of kynurenine. Since kynurenine is able to cross the 
placental and blood-brain barriers relatively easily, it should then lead to raised levels of 
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kynurenic acid in all these tissues. The main uncertainty is that, in tissues where Ro61-8048 
is present in very low concentration, kynurenine will still be converted to 3-HK and 
quinolinic acid at normal rates, rather than subnormal rates in the presence of KMO 
inhibition, so that the ratio of kynurenic acid to quinolinic acid may depend to some extent on 
Ro61-8048 penetration. This is potentially an important issue since it is the ratio between the 
levels of kynurenic acid (as a glutamate antagonist and neuroprotectant) and quinolinic acid 
(an NMDA receptor agonist and excitotoxin) that will determine the overall results of 
kynurenine pathway activity. The problem is likely to be moderated, however, by the fact that 
3-HK, like kynurenine itself, can pass the placental and blood-brain barriers, thus 
compensating for any lack of tissue penetration by Ro61-8048.  
     However, the kynurenine profile seen here is not unique to the administration of a 
synthetic chemical (Ro61-8048). The deletion of the kmo gene in mice has been reported to 
yield a similar profile of tryptophan metabolism to that observed here, with substantially 
increased levels of kynurenine, kynurenic acid and anthranilic acid in the brain but relatively 
little change (approximately 20%, albeit statistically significant) in the presence of quinolinic 
acid (Giorgini et al., 2013). That knockdown study did, however, include measurements of 
metabolite levels in the plasma and liver, both of which did exhibit a significant decrease in 
quinolinic acid production.  The constancy of quinolinate levels in the brain may, therefore, 
reflect the limited passage of ionised compounds across the blood-brain barrier, resulting in 
the entrapment of quinolinic acid within the tissue. This would support the growing belief 
that quinolinate concentrations should be regulated within strict limits within the brain if 
levels are not to be reached which would be neurotoxic (Guillemin 2012; Guillemin et al., 
2005; Stone et al., 2012). 
 
4.1  Neurodevelopment 
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     The ability of KMO inhibition to alter brain development supports the concept that the 
kynurenine pathway plays a key role in the early development of the CNS.  The pathway is 
certainly present in the embryonic brain (Beal et al., 1992; Cannazza et al. 2001; Guillemin et 
al., 2001, 2005; Schwarcz  and  Pellicciari, 2002; Walker et al., 1999), with the potential 
ability to modify glutamate receptor activation via the balance between the agonist quinolinic 
acid and the antagonist kynurenic acid. The high level of quinolinic acid prenatally which we 
have reported was also noted by Cannazza et al. 2001). 
     A variety of external influences affect brain development, including maternal infection or 
stress (Hornig et al., 1999; Meyer and Feldon 2010). The alterations of development are 
thought to underlie some neurological or psychiatric disorders in the offspring (Brown, 2006, 
2011; Hornig et al., 1999; Meyer and Feldon, 2010). Interferons generated during infection, 
are potent inducers of indoleamine-2,3-dioxygenase and KMO (Carlin et al., 1989; Alberati-
Giani et al. 1996; Silva et al. 2002; Brooks et al. 2016), and corticosteroids produced during 
stress activate TDO (Green and Curzon, 1975; Green et al., 1976; Nakamura et al., 1987; 
Young, 1981; Zunszain et al., 2012). These compounds could, therefore, mediate the effects 
of infection and stress on kynurenine metabolism.  
  Indeed any immune challenge to the mother or neonate which results, directly or indirectly, 
in the  activation of central glia or peripheral macrophages, or changes in the levels of 
cytokines or kynurenines in the foetal or neonatal CNS, would alter that balance of 
concentrations and could seriously perturb neural development and plasticity (Zavitsanou et 
al., 2014). This could in turn increase the risk of CNS disorders, such as schizophrenia, 
Alzheimer’s disease and Huntington’s disease and would be consistent with evidence that 
genetic abnormalities of the kynurenine pathway are linked to disorders such as 
schizophrenia (Holtze et al., 2012; Sathyasaikumar et al., 2011; Stone  and  Darlington, 
2013). The blockade of NMDA receptors by kynurenic acid produces neurochemical and 
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behavioural changes which have been likened to those seen in schizophrenia (du Bois  and  
Huang 2007; Harris et al., 2003) and related to altered levels of kynurenic acid in patients as 
discussed above. 
     Overall, the present data strongly support the concept that constitutive activity of the 
kynurenine pathway during embryogenesis is intimately involved in early brain development. 
This conclusion has important implications for the converse possibility that external factors 
promoting or suppressing basal activity may interfere with brain development and, as a result, 
brain structure and function in the adult. Infection and stress activate the pathway and 
maternal exposure to these factors during pregnancy has been linked to the emergence of 
disorders such as schizophrenia in postnatal life. The kynurenine pathway could be a major 
contributor to that association. 
 
4.2  Mecp2+/- mice 
     Although Rett syndrome in now recognised and classified as a separate disorder, there are 
features of the syndrome during the regressive phase that closely resemble phenotypic aspects 
of ASD. Several groups have reported links between the kynurenine pathway and ASD 
including changes in the KMO gene (McFarlane et al., 2008) or in the levels of tryptophan, 
kynurenine, quinolinic or kynurenic acids in patients with ASD which could account for 
some symptoms of the condition via their actions on the nervous or immune systems 
(Boccuto et al., 2013; Casanova, 2007; Essa et al., 2013; McTighe et al., 2013; Schwartz 
2014; Zimmerman et al., 2005; Lim et al., 2016), while others have failed to find a 
relationship (Sweeten et al., 2006). A study which focussed on Rett syndrome concluded that 
the levels of kynurenine were increased in striatal regions of the post mortem human brain, 
whereas serotonin concentrations were reduced (Riederer et al., 1986). The authors concluded 
that the high kynurenine levels could be relevant to the seizures often experienced by patients 
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with Rett syndrome as a result of the increased generation of the NMDA receptor agonist 
quinolinic acid (Stone and Perkins, 1981; Stone and Darlington 2002).   
     The use of female Mecp2+/- represents an accurate and sex specific model of Rett 
syndrome since it is only female children who develop recognisable symptoms typically 
survive into adulthood.  The deletion results in far more severe difficulties in male children 
and is usually lethal in infancy.  The absence of changes in tryptophan metabolites in the 
Mecp2+/- mice might therefore indicate that changes in tryptophan metabolism along the 
kynurenine pathway are not altered in Rett syndrome without seizures. However, a mouse 
model with a single selected genetic mutation is not the same as a human being in which the 
effects of any genetic change have been partially compensated by behavioural adaptation or 
genetic modifiers. Disease phenotypes are typically less severe in mice and their onset more 
delayed. However, oxidative stress is known to precede the onset symptoms in mouse models 
of Rett syndrome (De Felice et al., 2014) and the fact that we did not observe significant 
alterations in kynurenine metabolism may suggest that this pathway is of lesser importance in 
the pathogenesis of Rett syndrome. It is also possible that the changes in kynurenine 
metabolism that have been described in ASD or Rett syndrome are secondary to the 
behavioural abnormalities, reflecting the complex physiological and psychological reaction to 
the primary cause in humans which would not be expected to be shared by mice.  Viewed 
overall, the results might indicate that the reported changes in kynurenine metabolism should 
be considered in the category of epi-phenomena possibly related more to the stress 
experienced by sufferers of ASD or Rett syndrome or to co-incident infections and chronic 
low level inflammation.  
     The observation that kynurenine levels were lower in the wild type C57BL/6J mice here 
than in the study of kmo deletion by Giorgini et al., (2013), whereas anthranilic acid levels 
were around 10-fold higher, may reflect the different genomic background of the animals 
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since the C57BL/6J mice used for the original conditional knockouts were subsequently 
back-crossed at least six times to an FVBN background, so that genomic features of the latter 
strain should predominate. Alternatively, the differences might indicate represent a gender 
difference since only female mice were used here, whereas Giorgini et al., (2013) do not 
specify gender and presumably used a mixed population. 
      In another respect, the use of these mice has served as a control of the new LC-MSMS 
system, since intrinsic variability in the analysis would be predicted to generate some 
spurious differences in metabolite concentrations. If the changes in tryptophan metabolism 
demonstrated above in KMO deficient animals are viewed as the positive control 
experiments, the failure to find differences between the Mecp2+/- mice and their normal 
controls can be taken to support the reliability, reproducibility and robustness of this LC-
MSMS system.  
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FIGURE LEGENDS 
 
Figure 1.  Tryptophan metabolism in adult female rat brains. 
The charts summarise the concentrations of (A) tryptophan, (B) kynurenine, (C) kynurenic 
acid, (D) 3-hydroxykynurenine, (E) xanthurenic acid, (F) anthranilic acid and (G) quinolinic 
acid in the brains of pregnant female rats 5h after the intraperitoneal administration of Ro61-
8048.  *P<0.05;  **P<0.01;  ***P<0.001 (paired t test, n = 3) 
 
 
 
Figure 2.  Tryptophan metabolism in adult female rat brains. 
The charts summarise the concentrations of (A) tryptophan, (B) kynurenine, (C) kynurenic 
acid, (D) 3-hydroxykynurenine, (E) xanthurenic acid, (F) anthranilic acid and (G) quinolinic 
acid in the brains of pregnant female rats 24h after the intraperitoneal administration of Ro61-
8048, a time at which there were no longer any significant differences (paired t test, n = 3). 
 
 
 
Figure 3.  Tryptophan metabolism in embryo rat brains. 
The charts summarise the concentrations of (A) tryptophan, (B) kynurenine, (C) kynurenic 
acid, (D) 3-hydroxykynurenine, (E) xanthurenic acid, (F) anthranilic acid and (G) quinolinic 
acid in the brains of rat embryos 5h after the intraperitoneal administration of Ro61-8048 to 
the mother.  ***P<0.001 (paired t test, n = 6). 
 
 
 
 
Figure 4.  Tryptophan metabolism in embryo rat brains. 
The charts summarise the concentrations of (A) tryptophan, (B) kynurenine, (C) kynurenic 
acid, (D) 3-hydroxykynurenine, (E) xanthurenic acid, (F) anthranilic acid and (G) quinolinic 
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acid in the brains of pregnant female rats 24h after the intraperitoneal administration of Ro61-
8048.  **P<0.01 (paired t test, n = 6). 
 
 
Figure 5.  Tryptophan metabolism in the brains of Mecp2+/- mice. 
The charts summarise the concentrations of (A) tryptophan, (B) kynurenine, (C) kynurenic 
acid, (D) 3-hydroxykynurenine, (E) xanthurenic acid, (F) anthranilic acid and (G) quinolinic 
acid in the brains of 3-6 week-old Mecp2+/- mice. No significant differences were observed 
between the knockdown animals and their normal controls (paired t test, n = 6). 
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Table 1. Values for ion MRM mode acquisitions 
m/z   DP  EP  CE  CXP  ST1 
Positive ion MRM mode acquisitions: 
Tryptophan     205.16/146.00   6  10  25  10   -13 
2H5-tryptophan    210.16/151.00    6  10  25  10   -13 
Kynurenine     209.10/94.10   71  10  21  12   -13 
2H6-kynurenine    215.10/98.10   71  10  21  12   -13 
Kynurenic acid    189.93/144.00   46  10  30  12   -13 
2H5-kynurenic acid    194.93/149.00   46  10  30  12   -13 
Anthranilic acid    138.20/92.00   41  10  29  12   -13 
Anthranilic acid, confirmation  138.20/120.20   41  10  15  10   -13 
3-hydroxykynurenine    225.10/110.10   61  10   23  14   -13 
3-hydroxykynurenine, confirmation  225.10/208.20   33  10  14  10   -13 
3-hydroxyanthranilic acid   154.10/80.10   35  10  36  15   -13 
Xanthurenic acid    206.00/160.00   45  10  44  12   -13 
 
Negative ion MRM mode acquisitions:  
quinolinic acid     166.044/122.100   -30   -10   -14   -9   13 
13C3,15N-quinolinic acid    170.044/126.100   -30   -10   -14   -9   13 
picolinic acid      121.989/77.800   -120   -10   -16   -31   13 
2H3-picolinic acid    124.880/81.000   -30   -10   -15   -10   13 
 
Abbreviations: Declustering Potential (DP), Entrance Potential (EP), Collision Energy (CE), Exit Potential (CXP), Prefilter (ST1)  
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Highlights 
 
 - Pregnant rats were treated with an inhibitor of kynurenine-3-monoxygenase 
 - Levels of several kynurenine metabolites increased in the maternal and foetal brains 
- The maternal changes at 5h disappeared by 24h, but were maintained in embryos 
- No changes were noted in the brains of Mecp2+/- mice 
- KMO inhibition but not Mecp2+/- suppression alters kynurenine metabolism 
 
 
 
 
 
